Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tat Oyi vaccine in HIV-1 seropositive patients
NCT01793818Phase 2
Key facts
- Status
- Unknown
- Start
- Feb 2013
- Primary completion
- Mar 2016
- Countries
- 1
- Sponsor
- Biosantech
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Drugs
- tat oyi
- Conditions
- human immunodeficiency virus infection (HIV)
01
Overview
Phase 2, randomised, double-blind trial of tat oyi in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Biosantech. Primary endpoints: Optimal vaccine dose at 2 years, Plasma viremia at 2 years and 1 more. Status: unknown.
02
Design
4 arms- Study design
- RandomizedDouble-blind
Placebo
Tat Oyi 11 µg
Tat Oyi 33 µg
Tat Oyi 99 µg
03
Endpoints
Primary
Optimal vaccine dose
Plasma viremia
Undesirable events
Secondary
Tat antibodies
Beyond the preview
Go deeper on NCT01793818.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01793818.